News
Scaffold Biotech’s Vaccine: 90% Efficacy and a Promising Tool for the National Tick Control Plan
The startup Scaffold Biotech, founded by Institut Pasteur de Montevideo researchers Agustín Correa and Matías Machado, is developing a tick vaccine that showed 90% effectiveness in field trials during the evaluation period. The vaccine will now undergo efficacy trials under controlled conditions, carried out by the Ministry of Livestock,...
One year after funding: Startup advancements
A year ago, LAB+ Company Builder closed its first round of funding, securing $750,000 in financing for each of its first four startups. These companies used the investment to advance their science and technology. Scaffold Biotech, which is developing a vaccine to protect cattle from ticks, optimized the production of its components and tested...
Locbio’s Founder Named Coordinator of CEBEM
Felipe Trajtenberg, founder of the start-up Locbio, has been appointed as the new coordinator of the Structural Biology Center of Mercosur (Centro de Biología Estructurall del Mercosur, CEBEM). CEBEM is a collaborative network of scientific research groups working to advance structural biology and bioimaging capabilities in South America. It...
Read the first edition of our newsletter here.
(It’s in Spanish, but there’s a translation option at the top right of the menu)
LAB+ in the Media:
Local
Forbes Uruguay – Interview with Carlos Batthyány about LAB+ and the Institut Pasteur de Montevideo
Búsqueda – International call for startups, interview with Carlos Batthyány and Paul Elberse
En Perspectiva – Agustín Correa and Matías Machado, from Scaffold Biotech: Uruguayan company works with protein engineering to reach a ‘new frontier in vaccination’
Modo País (Channel 5) – Guska, created by Pilar Moreno and Gonzalo Moratorio
En Perspectiva – Felipe Trajtenberg, from LoCBio: reprogramming bacteria to treat colorectal cancer
La Diaria – What do the first four start-ups of the LAB+ seek to develop?
Telemundo (Channel 12) – Scaffold Biotech: more efficient vaccines for animals
En Perspectiva – Director of the Institut Pasteur de Montevideo talks about the LAB+ iniciative and Gonzalo Moratorio explains the science behind the start-up Guska
Subrayado (Channel 10) – LAB+ closed its first financing cycle
Radio Carve – Director of the Institut Pasteur de Montevideo talks about LAB+
La Diaria – Conversations with the first four biotech start-ups funded by LAB+
El País (Business) – Institut Pasteur de Montevideo presented its first four start-ups
Uruguay XXI – Institut Pasteur de Montevideo presented its first four start-ups
Telenoche (Channel 4) – Juan Pablo Tosar talks about the start-up B4-RNA
Ambito – The Institut Pasteur will invest US$25M in Uruguayan start-ups
El Observador – Four start-ups from the Institut Pasteur de Montevideo obtained financing for US$ 5 million: which are they?
Telenoche (Channel 4) – Institut Pasteur de Montevideo presented its LAB+ Company Builder initiative
Montevideo Portal – The Institut Pasteur de Montevideo presents a program to support scientific-technological companies
International
Yale Podcasts – Interview with Gonzalo Moratorio, Guska’s founder
Tekios – LAB+ international call for scientific projects and start-ups
SwissInfo – LAB+ international call for scientific projects and start-ups
Latin American Post – LAB+ pioneers a new era of scientific start-ups in Uruguay and beyond.
Infobae – Closing of first round of financing for LAB+.
EFE – The Institut Pasteur de Montevideo presents LAB+, with four start-ups.
Investing – The Institut Pasteur de Montevideo launches the LAB+ iniciative.
ABC (Paraguay) – With four start-ups, the Institut Pasteur de Montevideo launches the LAB+.
Bloomberg – New Venture Capital Fund Eyes Latin American Science Start-ups.
Bloomberg online – New venture capital fund sets its sights on Latin American scientific start-ups.
Perfil – A new venture capital fund targets Latin American science.
iProUP – Support for startups: Ficus Capital, biotech fund, looks for unicorns in Latin America.
Yahoo Finances – Biotech fund seeks unicorns in LatAm.